icer white paper affordable access to glp-1 obesity medications 2025 Medications: Strategies to Guide Market Action & Policy Solutions A Cost That's Hard to

Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.

Positive results made simple with Rogaine no wonder most men wish they started using it, sooner

Our robust approach to helping plan sponsors control costs for weight management GLP-1s includes flexible coverage, cost and care management strategies.

This study was led by Yunha Noh - grateful to her and all of our collaborators for their important contributions

This Sunday's issue of Plain Medicine breaks down who qualifies, how to access the benefit, and what to ask your provider before July 1

Fralin Biomedical Research Institute researchers found that after a cocktail, study participants taking medications for diabetes and weight loss saw delayed effects from alcohol.